Clinical trials
Completed Tuberous Sclerosis trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
54 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2002 | 1 |
| 2005 | 2 |
| 2007 | 2 |
| 2008 | 2 |
| 2009 | 4 |
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 2 |
| 2013 | 6 |
| 2014 | 3 |
| 2015 | 3 |
| 2016 | 6 |
| 2018 | 2 |
| 2019 | 2 |
| 2020 | 3 |
| 2021 | 1 |
| 2022 | 9 |
| 2023 | 1 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 54 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Children's Hospital Medical Center, Cincinnati | 7 |
| Jazz Pharmaceuticals | 3 |
| Nobelpharma | 3 |
| Novartis Pharmaceuticals | 3 |
| University of California, Los Angeles | 3 |
| Beijing Children's Hospital | 2 |
| Dana-Farber Cancer Institute | 2 |
| Longboard Pharmaceuticals | 2 |
| Marinus Pharmaceuticals | 2 |
| National Heart, Lung, and Blood Institute (NHLBI) | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Tuberous Sclerosis | 54 |
| Lymphangioleiomyomatosis | 10 |
| Epilepsy | 9 |
| Seizures | 7 |
| Angiofibroma | 5 |
| Angiomyolipoma | 4 |
| Hereditary Sensory and Autonomic Neuropathies | 4 |
| Astrocytoma | 3 |
| Autistic Disorder | 3 |
| Epilepsies, Myoclonic | 3 |
Trials
Showing 76 to 54 of 54. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.